The impact of methylprednisolone and rituximab on podocyte injury caused by puromycin aminonucleoside
Authors:
Open Access
- 10 December 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1504834
Abstract
Introduction: To explore how MP and RTX impact TRPC6's expression and localization, and assess MP's and RTX's effects on podocyte injury and recovery. Methods: MPC5 cells were simultaneously grown alongside a control group and under various conditions: exposure to puromycin aminonucleoside (PAN) stimulation, treatment with methylprednisolone (MP), and treatment with rituximab (RTX), and a combined treatment with both MP and RTX. Results: At 8, 24, and 48 h, CCK-8 assay showed that PAN (50 μg/mL) had a decrease in cell viability and an increase in cell death, and it could be used as the optimum concentration to induce podocyte injury; MP (100 ng/mL) and RTX (100 μg/mL) maintained cell viability and had minimal impact on cell morphology, and they were the best concentrations. Following 24 and 48-h exposure to MP or RTX, there was a decrease of 30%–50% in apoptosis rates by flow cytometry in comparison to the group stimulated with PAN, accompanied by a substantial reduction in nearly 10%–60% of TRPC6 mRNA and 5%–20% of protein levels which were measured using qRT-PCR and western blot analyses, akin to the observed decrease in levels of IL-1β and IL-18. Additionally, calcium entry showed considerable reductions after 8, 24, and 48 h of MP treatment relative to the PAN-stimulation group, paralleling the effect seen with 24-h RTX treatment. Discussion: Therefore, MP and RTX safeguarded podocytes, and averted proteinuria by decreasing podocyte apoptosis, diminishing TRPC6 mRNA and protein levels, and suppressing inflammatory markers and calcium entry.Keywords
This publication has 47 references indexed in Scilit:
- PM2.5 from biofuel smoke induces inflammatory response through the TRPC6/Ca2+/NLRP3 signaling pathwayEnvironmental Geochemistry and Health, 2025
- Targeting Heparanase Attenuates Podocyte Injury Induced by Puromycin AminonucleosideJournal of Cellular Physiology, 2025
- Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: a multicenter studyPediatric Nephrology, 2024
- Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial)Clinical and Experimental Nephrology, 2023
- An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosisCellular and Molecular Life Sciences, 2023
- Targeted therapy in glomerular diseasesJournal of the Formosan Medical Association, 2023
- Dysfunction of the Klotho-miR-30s/TRPC6 axis confers podocyte injuryBiochemical and Biophysical Research Communications, 2021
- Astragaloside IV inhibits palmitic acid-induced apoptosis through regulation of calcium homeostasis in mice podocytesMolecular Biology Reports, 2021
- Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimenPediatric Nephrology, 2020
- Role of Podocyte Injury in Glomerulosclerosis2019